His career in the pharmaceutical industry began in 2004 at Sandoz (Novartis group) where he held positions of increased responsibility in finance, IT and commercial sections before moving to general management roles.

Source: https://timesofmalta.com/articles/view/fabio-sperandei-new-president-novartis-cyprus-malta.1015767

Sandoz division global sales were $9.2 billion (CHF8.4 billion) in 2022 compared to $41.3 billion from the innovative medicine division of Novartis.

Source: https://www.swissinfo.ch/eng/business/after-spin-off-sandoz-sets-out-to-make-cheap-medicine-profitable/48866374?utm_campaign=swi-rss&utm_source=multiple&utm_medium=rss&utm_content=o

The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties.

Source: https://247wallst.com/investing/2023/12/11/6-health-care-dividend-stocks-to-by-hand-over-fist/